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Telavancin and daptomycin activity against meticillin-resistant Staphylococcus aureus strains after vancomycin-resistance selection in vitro Meticillin-resistant Staphylococcus aureus (MRSA) is a major threat worldwide. Vancomycin is still the drug of choice (Liu et al., 2011) , but clinical failure in patients with serious Gram-positive infections has been increasingly reported with infections caused by MRSA strains with higher vancomycin MICs (Jones, 2006; Neoh et al., 2007; Petrosillo et al., 2010; Sakoulas et al., 2004) . Daptomycin is a lipopeptide with a good activity against MRSA, vancomycinintermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) (Jung et al., 2004; Moubareck et al., 2009) . The emergence of S. aureus strains with a daptomycin MIC at the upper range of susceptibility has been reported (van Hal et al., 2011) . An association between reduced susceptibility to daptomycin and to vancomycin in S. aureus has been found (van Hal et al., 2011) . In these cases, no definitive daptomycin resistance mechanism has been identified (Hobbs et al., 2008; van Hal et al., 2011) . It has been shown that a thickened cell wall is a common characteristic for VISA strains: the thickened cell wall serves as a physical barrier against the penetration of vancomycin molecules (Cui et al., 2005; Gander et al., 2005; Peleg et al., 2012) . Daptomycin and vancomycin molecule sizes are comparable, and it has been suggested that a thickened cell wall acts as a common obstacle to both drugs' penetration. This would be a possible explanation of the correlation between vancomycin and daptomycin resistance. Telavancin is active against MRSA, VISA and VRSA (Cui et al., 2003; Draghi et al., 2008; Kanafani, 2006; Pace et al., 2003) . We evaluated the in vitro activity of telavancin and daptomycin against MRSA strains with a vancomycin MIC ¡0.5 mg ml
21
, and again after the induction of the same strains to a vancomycin MIC of 2 mg ml
.
A total of 19 MRSA strains with a vancomycin MIC ¡0.5 mg ml
, isolated from patients with bloodstream (nine patients), respiratory tract (four patients), and skin and soft skin infections (six patients), were considered. All the isolated strains showed a vancomycin MIC ¡0.5 mg ml 21 when tested with the VITEK 2 system (bioMérieux . Four (21 %) of the initial MRSA strains were found to be oxacillin susceptible with a MIC of 0.5 mg ml 21 at 24 and 48 h. This result was confirmed with a Kirby-Bauer test. At 24 h, 13 (68.4 %) and six (31.6 %) of the strains showed a telavancin MIC of 0.5 and 1 mg ml
, respectively. At 48 h, four more strains had an increased telavancin MIC of 1 mg ml
. None exceeded this value. At 24 h for daptomycin, only one strain (5.3 %) was confirmed with a MIC of 0.25 mg ml
; three (15.8 %) had a MIC of 0.5 mg ml 21 and the remaining 15 strains (78.9 %) showed a MIC of 1 mg ml
. The MIC of daptomycin for the strains after 48 h of incubation showed the same results as at 24 h. Electron microscopy was performed before and after resistance selection, and showed a cell wall thickening in all the MRSA strains with a vancomycin MIC of 2 mg ml 21 (Fig. 1) .
We have demonstrated that an in vitro increase of vancomycin MIC in MRSA strains does not affect telavancin and Cui, L., Ma, X., Sato, K., Okuma, K., Tenover, F. C., Mamizuka, E. M., Gemmell, C. G., Kim, M. 
